Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Coronary Interventions]

Conclusions— In the TAO trial, peak procedural ACT ≥250 s was associated with increased bleeding risk in non–ST-segment–elevation acute coronary syndrome patients treated with unfractionated heparin plus GPIs. This threshold was increased to 290 s when performing radial approach. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique identifier: NCT01076764.

http://circinterventions.ahajournals.org/cgi/content/short/11/6/e006084?rss=1

Source: Circulation: Cardiovascular Interventions - June 12, 2018 Category: Cardiology Authors: Dillinger, J.-G., Ducrocq, G., Elbez, Y., Cohen, M., Bode, C., Pollack, C., Nicolau, J. C., Henry, P., Kedev, S., Wiviott, S. D., Sabatine, M. S., Mehta, S. R., Steg, P. G. Tags: Percutaneous Coronary Intervention, Stent, Treatment, Complications, Thrombosis Coronary Interventions Source Type: research